{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:44:29Z","timestamp":1790181869680,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 18K 15927"],"award-info":[{"award-number":["JP 18K 15927"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.lungcan.2021.05.023","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T23:27:01Z","timestamp":1621898821000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non\u2013small cell lung cancer patients treated with osimertinib"],"prefix":"10.1016","volume":"158","author":[{"given":"Renpeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-6096","authenticated-orcid":false,"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4456-429X","authenticated-orcid":false,"given":"Tetsuzo","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-3469","authenticated-orcid":false,"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.lungcan.2021.05.023_bib0005","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.05.023_bib0010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu. Rev. Biochem."},{"issue":"12","key":"10.1016\/j.lungcan.2021.05.023_bib0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","article-title":"The HER family and cancer: emerging molecular mechanisms and therapeutic targets","volume":"13","author":"Sergina","year":"2007","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.023_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.023_bib0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.023_bib0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrclinonc.2010.64","article-title":"Targeted therapy in non-small-cell lung cancer\u2013is it becoming a reality?","volume":"7","author":"Janku","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.lungcan.2021.05.023_bib0035","doi-asserted-by":"crossref","first-page":"52862","DOI":"10.18632\/oncotarget.10594","article-title":"Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer","volume":"7","author":"Ling","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.023_bib0040","first-page":"2185","article-title":"Prognostic significance of the expression of HER family members in primary osteosarcoma","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.023_bib0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-011-1606-z","article-title":"In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer","volume":"132","author":"Spears","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.023_bib0050","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.023_bib0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.023_bib0060","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lungcan.2021.05.023_bib0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/PO.19.00333","article-title":"Targeting HER2 alterations in non\u2013small-cell lung cancer: a comprehensive review","volume":"4","author":"Zhao","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.023_bib0070","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1073\/pnas.1915531117","article-title":"A strategy for designing allosteric modulators of transcription factor dimerization","volume":"117","author":"Oasa","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2021.05.023_bib0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2018.10.019","article-title":"Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study","volume":"126","author":"Koga","year":"2018","journal-title":"Lung Cancer"},{"issue":"suppl_1","key":"10.1016\/j.lungcan.2021.05.023_bib0080","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.023_bib0085","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.023_bib0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.023_bib0095","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.023_bib0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamaoncol.2016.0333","article-title":"Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors: a review","volume":"2","author":"Piotrowska","year":"2016","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.023_bib0105","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer","volume":"16","author":"Tan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.023_bib0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.023_bib0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23582-1","article-title":"Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes","volume":"8","author":"Klaesson","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2021.05.023_bib0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fonc.2013.00271","article-title":"In situ protein detection for companion diagnostics","volume":"3","author":"Gremel","year":"2013","journal-title":"Front. Oncol."},{"issue":"42","key":"10.1016\/j.lungcan.2021.05.023_bib0125","doi-asserted-by":"crossref","first-page":"72127","DOI":"10.18632\/oncotarget.19552","article-title":"Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay","volume":"8","author":"Ota","year":"2017","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.lungcan.2021.05.023_bib0130","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.023_bib0135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1541-7786.MCR-11-0531","article-title":"In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy","volume":"10","author":"Gajadhar","year":"2012","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.023_bib0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00109-014-1187-5","article-title":"ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways","volume":"92","author":"Fichter","year":"2014","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.023_bib0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","article-title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","volume":"4","author":"Sridhar","year":"2003","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.023_bib0150","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.023_bib0155","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2021.05.023_bib0160","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2021.05.023_bib0165","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-04-2748","article-title":"HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2\/HER3 heterodimer formation in lung cancer cells","volume":"65","author":"Hirata","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2021.05.023_bib0170","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.tibs.2017.05.003","article-title":"Close encounters - probing proximal proteins in live or fixed cells","volume":"42","author":"Lonn","year":"2017","journal-title":"Trends Biochem. Sci."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:57:58Z","timestamp":1759237078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221004037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":34,"alternative-id":["S0169500221004037"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.023","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non\u2013small cell lung cancer patients treated with osimertinib","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}